Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data

Inflammatory Bowel Diseases

Volumn 17, Issue 3, 2011, Pages 787-794

  Lund, Jennifer L ^a   Stürmer, Til ^a   Porter, Carol Q ^b   Sandler, Robert S ^a,c   Kappelman, Michael D ^c  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

epidemiology; thiazolidinediones; ulcerative colitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADALIMUMAB; BUDESONIDE; INFLIXIMAB; INSULIN; METHOTREXATE; ORAL ANTIDIABETIC AGENT; SALICYLIC ACID; STEROID;

ADULT; ARTICLE; COLON RESECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE EXACERBATION; DRUG USE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; SECONDARY ANALYSIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; COHORT STUDIES; COLITIS, ULCERATIVE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951661130     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21348     Document Type: Article

References (24)

1. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007; 13: 451-461. (Pubitemid 46668251)
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 1424-1429. (Pubitemid 350181588)
3. The Crohn's and Colitis Foundation of America. Accessed August 2008.
4. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997; 272: 18779-18789. (Pubitemid 27318225)
5. Food and Drug Administration, CDER. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed August 2008.
6. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006; 55: 1341-1349. (Pubitemid 44277368)
7. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008; 134: 688-695. (Pubitemid 351312727)
8. Liang HL, Ouyang Q,. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol. 2008; 14: 114-119. (Pubitemid 351314337)
9. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999; 104: 383-389. (Pubitemid 29534322)
10. Centers for Disease Prevention and Control: National Diabetes Surveillance System. National Diabetes Fact Sheet, 2007.
11. Rajagopalan R, Iyer S, Perez A,. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab. 2005; 7: 161-169. (Pubitemid 40352730)
12. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158: 915-920. (Pubitemid 37323253)
13. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
14. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006; 163: 1149-1156. (Pubitemid 43987579)
15. Parsons L,. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Twenty-Fifth Annual SAS Users' Group International Conference. Cary, NC: SAS Institute; 2000: 1166-1171.
16. Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009; 169: 1395-1402.
17. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298: 2634-2643. (Pubitemid 350254955)
18. Solomon DH, Cadarette SM, Choudhry NK, et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 2009; 94: 2792-2798.
19. Guess HA,. Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf. 2006; 15: 81-92.
20. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11: 550-560. (Pubitemid 30660034)
21. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166: 348-354. (Pubitemid 47216808)
22. Sturmer T, Rothman KJ, Glynn RJ,. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf. 2006; 15: 698-709. (Pubitemid 44649508)
23. Aberra FN, Brensinger CM, Bilker WB, et al. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005; 3: 459-465. (Pubitemid 40616911)
24. Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004; 126: 665-673. (Pubitemid 38298314)